Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review

References

• Girolomoni G, Strohal R, Puig L. The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venerol. 2017;31:1616–1626.
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.
   PubMedGoogle Scholar
• Global report on Psoriasis. Geneva: World Health Organization (WHO); 2016.
   Google Scholar
• Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386:983–994.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Capon F, Berker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11–27.
   PubMed Web of Science ®Google Scholar
• Caso F, Del Puente A, Oliviero F, et al. Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidence from literature and a recent cross-sectional study. Clin Rheumatol. 2018;37:579–586.
   Web of Science ®Google Scholar
• Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67:955–959.
   PubMed Web of Science ®Google Scholar
• Elysoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int. 2016;36:603–612.
   PubMed Web of Science ®Google Scholar
• Cauli A, Mathieu A. Th17 and interleukin 23 in the pathogenesis of psoriatic arthritis and spondyloarthritis. J Rheumatol. 2012;89:15–18.
   Google Scholar
• Espinoza LR, Berman A, Vasey FB, et al. Psoriatic arthritis and acquired immunodeficiency syndrome. Arthritis Rheum. 1988;8:1034–1040.
   Google Scholar
• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73.
   PubMed Web of Science ®Google Scholar
• Piskin G, Sylva-Steenland RMR, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176:1908–1915.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Raychaudhuri SP. IL-23/IL-17 axis in spondyloarthritis-bench to bedside. Clin Rheumatol. 2016;35:1437–1441.
   PubMed Web of Science ®Google Scholar
• Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and TH17 cytokines. Curr Rheumatol Rep. 2007;9:461–467.
   PubMedGoogle Scholar
• Tonel G, Conrad C, Laggner U, et al. Cutting edge: a critical role for IL-23 in psoriasis. J Immunol. 2010;185:5688–5691.
   PubMed Web of Science ®Google Scholar
• Cuchacovich R, Espinoza LR. Ustekinumab for psoriatic arthritis. Lancet. 2009;373(9664):605–606.
   PubMed Web of Science ®Google Scholar
• Caso F, Del Puente A, Peluso R, et al. Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs. 2016;21(1):69–79.
   PubMed Web of Science ®Google Scholar
• Nast A, Boehncke WH, Mrowietz U, et al. and the Deutsche Dematologic Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD). S3 – guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10:S1–95.
   Web of Science ®Google Scholar
• Hsu S, Papp KA, Lebwohl MG, et al. and the national foundation medical board. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148:95–102.
   PubMed Web of Science ®Google Scholar
• Canadian Psoriasis Guidelines Addendum Committee. Addendum to the Canadian guidelines for the management of plaque psoriasis. J Cut Med Surg. 2016;20(5):375–431.
   PubMed Web of Science ®Google Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3- guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – short version – EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venerol. 2015;29:2277–2294.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gaujoux-Viala C, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4–12.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499–510.
   PubMed Web of Science ®Google Scholar
• Coates LC, Ritchlin CT, Kavanaugh AF. GRAPPA treatment recommendations: and update from the GRAPPA 2013 annual meeting. J Rheumatol. 2014;41:1237–1239.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med. 2017;17(1):65–70.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Papp K, Kircik L. Secukinumab: review of the clinical evidence from the pivotal studies ERASURE, FIXTURE, and CLEAR. J Clin Aesth Dermatol. 2016;9(6):suppl 1(S7-S12).
   Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318–1328.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–1339.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase-3 trial. Lancet. 2015;386(9999):1137–1146.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, and anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, and anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
   PubMed Web of Science ®Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2017. DOI:10.1111/bjd.15750.
   Web of Science ®Google Scholar
• Mease P, Hall S, Fitzgerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–1550.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525–1536.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Strober BE, Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–128.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–640.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. PSUMMIT 1 study group. Efficacy and safety of ustekinumab in paitients with active psoriatic arthritis: 1 year results of the phase 3, multicenter, double blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780–789.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. PSUMMIT 2 study group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumor necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990–999.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analysis from two phase III, multicenter, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis. 2016;75:1984–1988.
   PubMed Web of Science ®Google Scholar
• Sanchez IM, Sorenson E, Levin E, et al. The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review. Dermatol Ther (Heidelb). 2017;7:425–446.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Leonardi C, Griffiths CEM, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol. 2012;66:731–741.
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow up. Br J Dermatol. 2013;168(4):844–854.
   PubMed Web of Science ®Google Scholar
• Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167:1145–1152.
   PubMed Web of Science ®Google Scholar
• Campa M, Mansouri B, Warren R, et al. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther. 2016;6:1–12.
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Kreuger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events. JAMA. 2011;308(8):864–871.
   Google Scholar
• Yiu Z, Exton LS, Jabbar-Lopez Z, et al. Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis. J Invest Dermatol. 2016;136(8):1584–1591.
   PubMed Web of Science ®Google Scholar
• Rungapiromnan W, Yiu ZZN, Warren RB, et al. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176:890–901.
   PubMedGoogle Scholar
• Napolitano M, Costa L, Caso F, et al. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clin Rheumatol. 2017;36:1589–1593.
   PubMed Web of Science ®Google Scholar
• Almirall M, Rodriguez J, Mateo L, et al. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice. Clin Rheumatol. 2017;36:439–443.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Ortolan A, Lorenzin M, et al. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clin Rheumatol. 2018. Epub ahead of print. DOI:10.1007/s10067-017-3953-6.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49:162–175.
   PubMed Web of Science ®Google Scholar
• Zhou H, Hu C, Zhu Y, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2010;50:257–267.
   PubMed Web of Science ®Google Scholar
• Iskandar IYK, Warren RB, Lunt M, et al. Differential drug survival of second line biological therapies in patients with psoriasis: observational cohort study from the British association of dermatologists biologic interventions. Register (BADBIR). J Invest Dermatol. 2017. Epub ahead of print. DOI:10.1016/j.jid.2017.09.044.
   PubMed Web of Science ®Google Scholar
• No DJ, Inkeless MS, Amin M, et al. Drug survival of biologic treatment in psoriasis: a systematic review. J Dermatol Res. 2017. DOI:10.1080/09546634.2017.1398393
   Google Scholar
• Iannone F, Santo L, Bucci R, et al. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real life data from the biologic Apulian registry (BIOPURE). Clin Rheumatol. 2018;37:1141–1142.
   Google Scholar
• Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412–1419.
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patient with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66:228–234.
   PubMed Web of Science ®Google Scholar
• Cuchacovich R, Garcia-Valladares I, Espinoza LR, et al. Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J Rheumatol . 2012;39:187–193.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Bang B, Sand C. Combination of antitumor necrosis factor-α and antiIL-12/23 in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study. Br J Dermatol. 2016;174:1145–1146.
   PubMed Web of Science ®Google Scholar
• Xu P, Xie N, Ye C. Inhibitory effect of bispecific antibody targeting IL-12 p40 and TNFα simultaneously on psoriasis mice. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33:890–895.
   PubMedGoogle Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140:645–653.
   PubMed Web of Science ®Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralization by bimekizumab in psoriatic arthritis: evidence from preclinical and experiments and a randomized placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2017. Epub ahead of print. DOI:10.1136/annrheumdis-2017-212127.
   PubMed Web of Science ®Google Scholar
• Mammood F, Coates LC, Helliwell PS. Current concepts and unmet needs in psoriatic arthritis. Clin Rheumatol. 2017. Epub ahead of print. DOI:10.1007/s10067-2017-3908-y
   Google Scholar